Overview
Malignant gliomas are aggressive primary brain tumors characterized by rapid growth and poor prognosis, primarily including glioblastoma multiforme (GBM). These tumors exhibit distinct pathological features such as milieu-specific vascular changes and elevated levels of specific biomarkers in cerebrospinal fluid. 23Diagnosis
Cerebrospinal Fluid Analysis: Elevated adenylate kinase activity is consistently found in cerebrospinal fluid (CSF) of patients with malignant gliomas but not in benign tumors or controls. 3
Histopathological Examination: Essential for definitive diagnosis, assessing tumor grade and cellular characteristics.
Imaging Studies: MRI with contrast is crucial for tumor localization, size, and vascular characteristics indicative of malignancy. 2Management
Surgical Resection: Primary treatment aimed at maximal safe resection to reduce tumor burden.
Radiation Therapy: Post-surgical adjuvant radiation therapy is standard for enhancing survival in glioblastoma multiforme.
Chemotherapy: Temozolomide is a first-line chemotherapy agent often used in conjunction with radiation therapy for newly diagnosed GBM. [Evidence: Expert opinion]Special Populations
Pregnancy: Management strategies are limited due to risks associated with both tumor progression and treatment modalities; individualized care is essential. [Evidence: Expert opinion]
Pediatrics: Specific considerations for treatment intensity and long-term neurocognitive outcomes are necessary, though detailed evidence from abstracts is lacking. [Evidence: Expert opinion]
Elderly: Treatment approaches may be modified due to comorbidities and frailty, emphasizing palliative care alongside aggressive interventions when feasible. [Evidence: Expert opinion]Key Recommendations
Measure adenylate kinase activity in cerebrospinal fluid as a potential biomarker for distinguishing malignant gliomas from benign tumors and controls. (Evidence: Moderate) 3
Utilize MRI with contrast imaging to evaluate vascular changes characteristic of malignant gliomas, aiding in diagnosis and treatment planning. (Evidence: Moderate) 2
Consider individualized treatment plans for pregnant patients with malignant gliomas, balancing maternal and fetal risks with tumor management. (Evidence: Expert opinion)References
1 Malmqvist KG, Brun A, Inamura K, Martins E, Salford LG, Siesjö BK et al.. Proton microprobe and particle induced X-ray emission (PIXE) analysis for studies of pathological brain tissue. Scanning microscopy 1988. link
2 Rath I, Müller W. Milieu-specific vascular changes in malignant brain tumours. Acta neurochirurgica 1980. link
3 Ronquist G, Ericsson P, Frithz G, Hugosson R. Malignant brain tumours associated with adenylate kinase in cerebrospinal fluid. Lancet (London, England) 1977. link91320-4)